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Abstract
As a direct consequence of rising drug resistance among common nematodes of grazing animals, efforts toward state-of-theart vaccine development have clearly intensified in recent years, fuelled primarily by the advent of newer technologies in gene
discovery, by advancements in antigen identification, characterisation and production. In this regard, it is appropriate to review
progress that has been made in generating helminth vaccines and in particular, vaccines against common nematodes of
production animals for consumption. In like manner, it is prudent to evaluate barriers that have hindered progress in the past and
continue to present obstacles that must be solved when utilizing and depending on host immunity to attenuate parasitic
infections.
# 2006 Elsevier B.V. All rights reserved.
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1. Introduction
Twenty-one years ago, the Plasmodium falciparum
circumsporozoite gene, which encodes a key target
antigen for vaccine development, was cloned and
expressed (Dame et al., 1984; Enea et al., 1984). At that
time, it was considered a breakthrough in the
development of a cost-effective and stable alternative
for vaccination against a parasitic disease that affects
millions of people in endemic regions throughout the
world. Unfortunately, the logical outcome of this work,
* Corresponding author. Tel.: +44 131 445 6131;
fax: +44 131 445 6111.
E-mail address: smitd@mri.sari.ac.uk (W.D. Smith).

a viable recombinant vaccine, still eludes researchers
today (Graves and Gelband, 2003). This battle to
produce efficacious parasite vaccines is not unique to
Plasmodium. Of the few parasite vaccines that are
commercially available, nearly all are based on
attenuated organisms. In general, protection wanes
upon removal of the immunological agent and as such
the host requires repeated natural or artificial boosting to
maintain immunity. Even though they do not stimulate
sterile immunity as such, these and other potential
parasite vaccines could still be useful management tools
for controlling helminth disease. With the notable
exception of one available parasite vaccine for the
bovine lungworm, Dictyocaulus viviparus, there are no
commercially available vaccines for the control of
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helminth infections in ruminants. Liver flukes and
gastrointestinal nematodes are nearly always controlled
by a combination of anthelmintic drugs and pasture
management. Although these practices can be extremely effective, the advent of anthelmintic resistance
indicates that they are not sustainable.
In the last 15 years, considerable progress has been
made in identifying candidate vaccine antigens for
several important helminth species and many reviews
have been published recently (Knox and Smith, 2001;
Knox et al., 2003; Lightowlers et al., 2003; Newton
and Meeusen, 2003). The present review concentrates
on some of the obstacles that must be overcome to
contend with the enigmatic problem of obtaining
helminth vaccines for ruminants as well as numerous
strategies, most notably, targeted antigen discovery,
that are being used to circumvent them to achieve the
goal. In this regard, we describe some of the protective
antigens that have been identified in recent years with
emphasis on the most promising discoveries. More
complete lists of less recently discovered antigens can
be found elsewhere (Emery, 1996), though research
on many of these antigens seems to have been
abandoned.

2. Vaccine strategies
In the 1960s, it was discovered that infection with
Dictyocaulus larvae, which had been attenuated by
irradiation could stimulate a high degree of protection
against challenge with normal infective larvae. This
discovery led to the development of ‘‘Dictol’’, a
vaccine, which is still sold today. Attempts were
immediately made to extend the principle to the
gastrointestinal helminths and, the method worked
well in inducing protection under experimental
conditions for Haemonchus contortus and Trichostrongylus colubriformis in sexually mature sheep.
However, in field infections the protective effect was
either too weak or too variable to be a practical
proposition, particularly in young lambs. Attenuated
larval vaccines utilise the complex effector mechanisms that constitute naturally acquired immunity,
which, for many endoparasites are known to be
acquired more slowly in young animals and be subject
to disruption during pregnancy, lactation and by poor
nutrition.

The vaccine strategy currently enjoying most
success largely ignores the mechanisms of natural
immunity, but attempts to direct responses towards
potentially susceptible targets on or secreted by the
parasite. For example, with the cestodes, Taenia and
Echinococcus, molecules on the surface of the delicate
oncosphere stage are appropriate targets, whereas for
Fasciola hepatica, H. contortus and Ostertagia
ostertagi certain proteins excreted or secreted by
the parasite are also candidate protective antigens. The
latter are known as ES (excretory/secretory) antigens
and, because they are recognised by the host immune
system following infection, are classified as ‘‘natural’’
antigens. However, in the case of blood feeding
Haemonchus, the luminal surface of the intestine has
also been a particularly rich source of suitably
effective target molecules.
Examples of ES and gut protective antigens for
ruminant helminths are described in more detail
below. The general approach for identifying either
type of antigen has been first to screen candidate
protective fractions enriched for the parasite target in
preliminary protection trials, second to purify the
protective components as far as possible and finally to
isolate and express the genes which encode these so
that an efficacious recombinant protein can be
produced as a cost-effective vaccine antigen.
As the parasitic stages of the economically
important species of ruminant helminths cannot be
satisfactorily cultured in vitro, it can be relatively
difficult to obtain sufficient quantity of worms for the
first of these steps, and to collect enough material to
purify the antigen of interest by fractionation of the
starting material in step two is even more problematic.
Large numbers of parasite donor animals are required,
usually making the process very expensive, especially
if low yielding ES is the starting material. A recent,
sensitive analysis of parasite derived proteins
revealed just how many proteins are present in
Haemonchus ES (Yatsuda et al., 2003). With current
immunisation regimes, only a few micrograms of
contaminating protein are sufficient to stimulate a
strong antibody response, emphasising the difficulties
of ascribing protection to any particular molecule.
Most of the ES derived protective antigens were
obtained by a single simple fractionation step, a
process unlikely to purify any molecule from the
complex starting material completely. This limitation

W.D. Smith, D.S. Zarlenga / Veterinary Parasitology 139 (2006) 347–359

should be borne in mind with the protective antigens
described below.
The advent of bioinformatics and ‘‘gene mining’’
offers the possibility of identifying and synthesising
potentially protective parasite antigens directly, without having to isolate their equivalent native proteins
first. This approach is more fashionable than the
traditional ‘‘fractionate and vaccinate’’ process
described above. Despite considerable investment,
e.g. in vaccines for fleas, certain nematodes and the
salmon louse, it has not been successful to date. Part of
the problem is that if, as is the norm, the recombinant
antigen fails to protect in an animal trial, it is not
known whether the original target was an invalid
choice or whether in fact a potentially protective
antigen had been identified, but was not in the correct
format. Even if a partially protective recombinant
antigen was identified, it would be impossible to
determine its full potential without access to it in
native form. Given the expense of vaccine trials in
large animals and with so many potential molecules
and variants of such molecules to evaluate, it is hard to
maintain funder’s enthusiasm for any particular
antigen unless its native equivalent has been shown
to have good potential first. This probably explains
why the only successful parasite recombinant vaccine
developments to date have derived from the ‘‘fractionate and vaccinate’’ approach (Lightowlers et al.,
2003).

3. Cestode oncosphere antigens
Technically, the most advanced defined antigen
vaccines for any helminth parasite, are those for the
cyst stages of various cestode species where the
ruminant or pig acts as the intermediate host.
Extensive early ground work with these infections
showed that naturally acquired immunity was solid
and could be reproduced with preparations from the
parasite oncospheres (eggs). Following extensive
fractionation experiments with native oncosphere
proteins to identify the active components, highly
protective recombinant antigens were synthesised for
Taenia ovis and E. granulosus. The identification of
these antigens subsequently allowed the rapid development of homologous vaccines for the intermediate
hosts of T. saginata, E. multilocularis and T. solium
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(Lightowlers et al., 2003). However, as the importance
of all these parasites is mainly zoonotic with disease
mostly being restricted to the poor in developing
countries, it remains to be seen whether these scientific
successes can be translated into either commercial or
publicly funded vaccines, especially as control can
also be achieved by measures, such as better meat
inspection and improved sanitation.

4. Nematode and fluke ES antigens
While it is convenient to compartmentalise
helminth protective antigens as originating from the
ES or the gut, it should be borne in mind that the
precise boundaries between these sources are blurred.
ES are obtained by incubating worms harvested from
donor animals in simple media, usually for up to 48 h.
During this time some parasites may die, releasing gut
membrane proteins into the medium in a nonphysiological manner. For example, microsomal
aminopeptidases have been detected in Haemonchus
ES (Yatsuda et al., 2003), even though they are known
to be integral gut microvillar membrane proteins
(Smith et al., 1997). Equally, gut proteins, known to be
integral to the microvillar membrane because they can
only be extracted with detergent (Smith et al., 1999),
could subsequently be cleaved or secreted in a
physiological manner so that they or their fragments
appear in the ES (Yatsuda et al., 2003).
Cathepsin L from F. hepatica is an example of an
enzyme which is recognised by the ruminant following infection and which can induce high levels of
protection when used as a vaccine antigen. Vaccination of sheep with native enzyme reduced Fasciola egg
production by 70% and egg viability by more than
80% (Wijffels et al., 1994). Whereas one report in
cattle claimed 50% reduction in fluke numbers, this
effect was improved to 70% in cattle immunised with
cathepsin L combined with fluke haemoglobin and it
was found that almost 100% of the eggs shed by the
vaccinated animals failed to embryonate, suggesting
that parasite transmission would be enormously
reduced (Dalton et al., 1997).
Striking protective effects have been reported
against Haemonchus, using preparations enriched
for two proteins of 15 and 24 kDa from adult worm
excretory–secretory products (Schallig et al., 1997).
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These antigens are recognised serologically by
infected sheep, and though related to similar
molecules in Ancylostoma (termed ASPs) their
biological function has not yet been determined. At
first it was not possible to successfully immunise
growing lambs with these antigens (Vervelde et al.,
2001), as might be predicted from the observation that
natural immunity is slower to develop in lambs than
mature sheep. Interestingly, this problem seems to
have been overcome through a different choice of
adjuvant, although, because whole ES was used in the
trial, it was by no means clear whether protection
could be attributed to the 15 and 24 kDa components
alone (Vervelde et al., 2003). Unfortunately, attempts
to reproduce protection with various recombinant
versions of the 15 and 24 kDa molecules have not yet
been successful (Vervelde et al., 2002).
In two separate trials a thiol-binding fraction of the
ES from adult O. ostertagia reduced the egg counts of
vaccinated calves by about 60%, though there was no
effect on worm numbers (Geldhof et al., 2002, 2004).
The same fraction, but from a detergent extract of O.
ostertagi, was ineffective. In contrast, trials with
Haemonchus found protection through lower egg
counts and worm burdens with a detergent fraction of
worm membranes, but not with a fraction extracted
with saline. However, a thiol-binding fraction from
Haemonchus ES also reduced homologous egg and
worm counts by about 50% (Bakker et al., 2004).

5. Nematode and fluke gut antigens
The gut membrane approach was first applied
successfully to ticks in research, which culminated in
the launch of the recombinant vaccine against
Boophilus microplus, the Australian cattle tick (Willadsen et al., 1995). The principle is straightforward.
The host is immunised with appropriate gut membrane
proteins from a haematophageous parasite and a high
titre circulating antibody response is raised. When the
parasite subsequently feeds on the host, it ingests
antibodies, which bind to functional proteins on the
brush border of its intestinal cells, so that its digestive
processes are compromised, leading to starvation, loss
of fecundity and weakness. Eventually, the parasite
becomes detached and, in the case of the gastrointestinal species, is swept out of the gut by peristalsis.

This technique is showing great promise as a method
for controlling the blood feeder, H. contortus, from
which several different gut membrane proteins or
protein complexes have been isolated, giving more
than 80% reduction in eggs together with greater than
50% protection against worm numbers when tested
under experimental conditions (Jasmer et al., 1993;
Smith et al., 1994, 1997; Knox et al., 1999).
The best characterised and most effective of these
are known as H11 and H-gal-GP, which, respectively,
consist of a family of microsomal aminopeptidases
(Smith et al., 1997), and a complex containing
protective aspartyl and metallo proteases (Smith
et al., 2003a,b). It is presumed that all three protease
families are involved in the digestion of the blood
meal, a function compromised by antibodies in
vaccinated sheep. Immunisation with a combination
of H11 and H-gal-GP can offer substantial protection
against natural haemonchosis in grazing sheep (Smith
et al., 2001a). Attempts to produce recombinant
protective versions of these antigens has proved to be
frustratingly unsuccessful to date, though attempts are
still on-going (Newton and Meeusen, 2003; Smith
et al., 2003a,b).
In the case of H11, recombinant enzymically active
versions of three different aminopeptidase isotypes
have been synthesised. Sheep immunised with a
combination of these responded with serum titres of
enzyme neutralising antibodies indistinguishable from
animals immunised with native antigen, yet, unlike
these positive controls, they were not protected against
challenge. Three possible reasons for this failure were
discussed (Newton and Meeusen, 2003), two of which
involving glycosylation and contaminating proteins
are commented on further here.
Because the recombinant aminopeptidases were
derived from insect cells, they were glycosylated
differently from the native nematode enzymes, a
feature which Newton and Meeusen (2003) thought
could be critical. While this explanation may indeed
be valid, in our view the jury is still out and should
remain so. After all, native Bm86 from B. microplus
and native To45 from T. ovis (Lightowlers et al., 2003)
are also glycoproteins, yet these remain highly
protective when in recombinant form. Similarly, if
glycan alone was so crucial it might be expected that
preparations of native integral membrane intestinal
cell glycoproteins from, e.g. Caenorhabditis elegans
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or Teladorsagia circumcincta might be almost as
protective for Haemonchus as homologous preparations, but this is not the case (Redmond et al., 2004;
Smith et al., 2001b). If glycan is important for
protection, its effect must be due to conformational
epitopes rather than to simple sugars, else fully
denatured H11 would also protect.
The second explanation raised by Newton and
Meeusen (2003) was that the recombinant aminopeptidases were much less protective than native H11,
because the latter contained contaminating molecules
crucial for vaccine efficacy. Our view is that this
possibility is just as real as the wrong glycan theory.
Like many integral membrane proteins H11 is very
difficult to purify completely and detecting other
molecules within the type of native H11 vaccine
preparations listed by Newton and Munn (1999) is not
difficult. Perhaps immunisation with aminopeptidases
alone is insufficient to interfere adequately with
Haemonchus nutrient uptake, rather a combination of
digestive enzymes is needed for a really effective
vaccine.
Serum from sheep repeatedly infected and immune
to Haemonchus did not recognise the parasite’s
integral gut membrane proteins (Smith, 1993), leading
to the conclusion that, like certain Boophilus gut
proteins, they were ‘‘hidden’’ antigens. However,
more recent evidence has been provided that
Haemonchus gut membrane proteins are recognised
by vaccinated sheep or goats after a challenge
infection (Andrews et al., 1995; Jasmer et al.,
2003), though not to an extent where the anamnestic
response is capable of conferring protective immunity
(Andrews et al., 1995; Smith et al., 2001a).
A major advantage of the gut antigen approach is
that, because the mechanism of immunity is quite
different, it works in situations where natural
immunity to Haemonchus is weak or ineffective.
Thus, it has been shown that young lambs (Tavernor
et al., 1992; Smith, 1993), goat kids (Jasmer and
McGuire, 1991) and periparturient ewes (Andrews
et al., 1995) can be successfully immunised and that
some protective immunity is even transferred by
maternal antibody (Andrews et al., 1995). On the other
hand, when circulating vaccine antibody titres have
waned with time, a challenge infection does not boost
the immune response sufficiently rapidly or effectively
for the infection to be eliminated (Smith et al., 2001a).
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This is in stark contrast to conventional microbial
vaccines and would seem to be a serious disadvantage
because frequent immunisations might be required for
an effective level of protection to be maintained.
However, experimental evidence suggests otherwise.
The mechanism of protection in lambs immunised by
this method mainly affects late fourth stage and older
worms, whereas incoming larval stages, which are not
yet blood feeders are largely unaffected (Smith, 1993;
Smith and Smith, 1993). Thus, when immunised
lambs are subjected to repeated daily infections of
larvae, to mimic the situation in the field, faecal egg
counts and adult worm numbers are controlled by the
vaccine and the continued presence and activity of the
early larval stages stimulates a natural immunity
which is capable of replacing the effects of vaccine
immunity when this wanes (Smith, 1993; Smith and
Smith, 1993).
Attempts have been made to determine whether the
gut antigen approach could be successfully deployed
against species of nematode, which are not direct
blood feeders. The precise diet of economically
important genera like Ostertagia and Dictyocaulus is
not known, but they contain host immunoglobulin,
presumably ingested with mucus, tissue fluids and/or
serous exudates (Murray and Smith, 1994). Partial
success has been reported for O. ostertagi with
homologues of H11 and H-gal-GP, the most protective
Haemonchus antigens (Smith et al., 2000), but not for
T. circumcincta (Smith et al., 2001b). Interestingly,
antigen preparations from each of the latter species
were more effective against Haemonchus than a
homologous challenge, suggesting that the relative
failure was more likely to be due to inadequate
ingestion of host blood and therefore antibody, rather
than to a faulty antigen preparation (Smith et al., 2000,
2001b).
The glutathione S-transferases (GSTs) of F.
hepatica were chosen as candidate vaccine antigens
because homologous proteins from Schistosoma
mansoni and Schistosoma japonicum had been shown
to be protective in laboratory animal model infections
(Sexton et al., 1990). GSTs are hidden antigens
because they are not recognised serologically by sheep
or cattle infected by this parasite (Creaney et al.,
1995). Although they are present on the surface of the
gut cells of F. hepatica, GSTs are also distributed
in the parenchema and tegument of the parasite
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(Morrison et al., 1996), and so it is not clear whether
the mode of protection is analogous to that described
for the nematode gut membrane enzymes. GSTs are
thought to be involved in the fluke’s metabolism of
xenobiotics, transport of anionic compounds and the
detoxification of lipid peroxides.
Sheep and cattle immunised with native GSTs
isolated from F. hepatica have been protected on
average by 49% and 29%, respectively, although the
results from individual trials have been quite variable
(Creaney et al., 1995). The effect depended very much
on the adjuvant employed, but the formulation most
effective against F. hepatica did not work against
Fasciola gigantica (Estuningsih et al., 1997), suggesting that it was not possible to extrapolate results from
one Fasciola species to another. It is not clear by what
mechanism protection is induced but the simplest
possibility that anti-GST antibody neutralises these
enzymes, seems to have been discounted. Unfortunately, an attempt to achieve protection with a
recombinant GST in cattle was not successful (De
Bont et al., 2003).
Two South American groups have recently made
significant advances towards a vaccine for ovine liver
fluke. Piacenza et al. (1999) reported almost 90%
reduction in flukes following immunisation of lambs
with a leucine aminopeptidase isolated from a
detergent extract of adult F. hepatica, presumably
by a mechanism akin to that described for H11, the
Haemonchus microsomal aminopeptidase family.
Even more impressively, Almeida and others found
an almost complete absence of worms and liver
pathology in sheep immunised with a recombinant
version of a fatty acid binding protein derived from S.
mansoni known as Sm14, which is also a highly
effective against homologous challenge in rodent
models of schistosomiasis (Almeida et al., 2003).
Fasciola is believed to employ fatty acid binding
proteins to obtain fatty acids from host blood and it is
assumed that immunisation somehow blocks this
mechanism with fatal consequences for the parasite.
Even though the protective effect was reproduced in
two separate experiments, the number of sheep in
each group was small and, as the authors themselves
pointed out, more realistic field trials are required to
evaluate the product, which appears to be the closest
thing to a commercial fluke vaccine described to
date.

Compared to the abomasal species, little work has
been published recently on protective antigens for
small intestinal nematode parasites of ruminants. One
significant discovery described a clumping mechanism mediated by mucus antibodies whereby sheep
rejected T. colubriformis larvae. The antigen concerned, which is only found on the third larval stage
and its sheath, was identified as being composed of
35 kDa carbohydrate subunits and has been termed
CarLa (Harrison et al., 2003a,b). Similar molecules
are present in Nematodirus, Cooperia, Haemonchus
and Teladorsagia. It will be interesting to know
whether sheep can be immunised with this antigen
and, if so, whether they are protected. However, even
if this can be achieved, the problem of mass producing
this carbohydrate molecule cost effectively for a
commercial vaccine will remain.
A recombinant form of a 17 kDa globin-like
molecule from T. colubriformis (Frenkel et al.,
1992) was reported to reduce egg and worm counts
of young lambs by up to 50% after being given
intraperitoneally in Freunds adjuvant (Emery et al.,
1999). However, several other trials with the same
antigen given in different adjuvants and by other
routes produced mixed results (S.J. McClure, personal
communication).

6. Vaccine formulation and mode of delivery
The choice of adjuvant can be crucial for the
success of any vaccine. For example, using Haemonchus ES as antigen, much better antibody
responses and protection were achieved in lambs
with alhydrogel as adjuvant than with dimethyl
dioctadecyl ammonium bromide (Vervelde et al.,
2003). However, when alhydrogel was compared with
QuilA for immunising calves with ES thiol antigen
from O. ostertagi, only those immunised with QuilA
were protected (Geldhof et al., 2004). In the case of the
cestode oncosphere antigens, an adjuvant, which
stimulates a high titre antibody response is clearly
what is needed. With the nematode gut antigens the
requirement is the same, except that the response
should also be prolonged as much as possible. Because
the mechanisms of protection are not yet understood, it
is not yet clear what the requirements of adjuvants for
the fluke antigens are, but experiments to date have

W.D. Smith, D.S. Zarlenga / Veterinary Parasitology 139 (2006) 347–359

shown that the choice can be critical. For those species
of nematode, which reside in the small intestine, it
may be necessary for a recombinant vaccine to
stimulate facets of the mucosal response for effective
protection to be induced. A variety of adjuvants given
by different routes have been tested and the possibility
of using Salmonella vectors for achieving this has
been pursued (Brahmbhatt et al., 1997). The concept
of naked DNA vaccines is attractive particularly
because it could short circuit the need for producing
functional recombinant proteins. Unfortunately,
immunising sheep with DNA alone was not encouraging in the case of the 45W T. ovis antigen, since only
low titre antibody responses were invoked and no
protection against challenge was observed. However,
sheep primed by this naked DNA and boosted by the
same gene in an adenovirus vector had much higher
antibody titres and showed correspondingly high
levels of protection following challenge (Rothel et al.,
1997).

7. Impediments to vaccine development
In recent years, our understanding of innate and
acquired immunity, and our appreciation of the
complexity of host protective responses have
advanced tremendously. The dearth of available
parasite recombinant vaccines, however, indicates
that there remain hurdles in the quest to develop
functional reagents. A great number of these impediments relate directly to the antigen, such as: (1) correct
configuration and post translational modification; (2)
mode of administration and duration of the response;
(3) cost-effective production and dissemination; (4)
product stability. In addition to these, less tangible
obstacles such genetic diversity and millions of years
of adaptive and co-evolutionary forces among host and
parasite assemblages are being seen today as
formidable deterrents to achieving our goals. The
section to follow briefly synopsises these issues and
their roles in vaccine development.
7.1. Parasite genetic diversity
Researchers aspiring to develop nematode vaccines
based on naturally acquired mechanisms of immunity
have found this to be a formidable task, where
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numerous factors have contributed to the lack of
success, such as generating a product that is broadly
efficacious over a prolonged grazing season, maintaining a balance between reducing/eliminating disease pathology and preserving animal productivity,
producing a vaccine that is adaptable to a multitude of
management programs, and preserving sample stability and integrity (Sonstegard and Gasbarre, 2001).
The genetic complexity of the organisms suggests that
hundreds to thousands of antigens are potentially
involved in the cascade of the infection process.
Parasites undergo several well-defined life-cycle
changes even within their definitive hosts, which
present unique subsets of antigens for the immune
system to engage at each level of development.
Delineating which of these to target for recombinant
vaccine development has been a daunting task and has
been the subject of substantial review and discussion
(Sonstegard and Gasbarre, 2001).
In association with antigenic complexity, is the
potential role for both inter- and intra-population
genetic and antigenic diversity in the heartiness of the
species and its ability to circumvent host immune
intervention. Prior to the advent of PCR, research on
population diversity was limited to morphological
studies and anecdotal biological data at best. However,
as early as 1993 using mitochondrial DNA analysis,
Dame et al. (1993) demonstrated that substantial
genetic variation occurred both among and within
populations of O. ostertagi, to the extent that 98% of
the level of variation separating any two populations
was partitioned among individual worms within a
single population. Further studies showed that this
phenomenon was not unique to Ostertagia but present
in other trichostrongyles as well (Blouin et al., 1995).
Collectively, these data suggest that responses to any
given antigen may not necessarily be unilaterally
protective even against individuals within the same
population of worms. The plethora of ‘‘partially
protective’’ recombinant antigens amidst a higher
level of protection with the cognate naturally derived
antigens may be due, in part, to this type of genetic
diversity.
Due to population mixing among species of cattle
nematodes that results from the artificially high
migration rate of the host, genetic subdivision of
the parasites, even within broad geographical areas is
lacking. This leads one to hypothesise that other
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transmissible traits including but not limited to
resistance to drugs and vaccines would spread with
equal speed throughout a species (Viney, 1998; Blouin
et al., 1995). The rapid deployment of drug resistance
among parasitic nematode groups of sheep, as well as
that now being observed in trichostrongyles of cattle
lends credence to such a hypothesis.
It is difficult, to ascribe the less than stellar results
from field tests of recombinant vaccines to these
findings only. Indeed, some would argue that the lack
of genetic subdivision could simplify the identification
of unilaterally effective vaccines. Yet, within other
nematode genera, experiments involving heterologous
challenge suggest that antigens associated with
protective immunity are not necessarily conserved
among species or even among isolates of the same
species (reviewed in Maizels and KurniawanAtmadja, 2002). Consequently, it is prudent to
ascertain or consider the influence of protein polymorphism among natural populations during the
process of vaccine development.
7.2. Host genetic diversity
In like manner, when evaluating antigens one
cannot rule out genetic variability within the host
species and its relation to immunological nonresponsiveness to candidate vaccines (Quakyi et al.,
1989). Indeed, model predictions dating back to 1985
concluded that controlling parasitism by vaccinating
herds that were genetically heterogeneous in their
ability to mount protective responses would be
extremely difficult (Anderson and May, 1985). To
this end, evidence has been advanced demonstrating
that genetics plays a role in innate or acquired
resistance within a herd of nematode infected animals
where Leighton et al. (1989) showed that the number
of nematode eggs/gram (EPG) in feces of pastured
cattle was strongly influenced by host genetics.
Further, research demonstrated that high EPG values
were not randomly distributed throughout the herd,
but that the majority of parasite transmission was the
result of a small percentage of ‘‘highly susceptible’’
animals within the herd (Genchi et al., 1989). This
suggests that vaccines to reduce parasite transmission
and therefore host pathogenicity may need only be
targeted to the small population of susceptible hosts
within a herd. Work is currently under way to identify

genetic markers for delineating nematode susceptible
and resistant cows (Gasbarre et al., 2001; Sonstegard
and Gasbarre, 2001) and sheep (Beh et al., 2002) to
assist in managing this problem, naturally; however,
one can envision that further attenuation might be
achieved when coupled with an appropriately
designed and administered vaccine.
The contributions that animal modeling has made
to our understanding of immunity and the polarisation
of immune responses to infection via antigen specific
responses are innumerable. Still, examples persist in
large animal research demonstrating deviations from
conventional wisdom, such as: (1) the unlikely downregulation of IL-4 receptor a and IL-13 receptor a-1
transcription during acute nematode induced Th2 host
responses in swine (Zarlenga et al., 2004); (2) the
significantly lower levels of IL-12b2 receptor transcription in swine lymphocytes (Solano-Aguilar et al.,
2002) which may influence the timing and intensity of
Th1-associated responses; (3) the concomitant elevation of IFN-g and IL-4 transcription in nematode
(Canals et al., 1997) and virus (Waldvogel et al., 2000)
infected cows; (4) the near absence of rapid expulsion
of adult worms in large animals and man (Behnke
et al., 1992). Although small animal modeling has
shown quite convincingly that mechanisms involved
in antigen recognition are generally conserved among
a broad spectrum of hosts, it cannot be assumed that
specific parasite immune evasion mechanisms are
congruent across model and natural host systems.
Model systems may not accurately mimic the
parasite’s natural environment or the inter-workings
of the host–parasite relationship. Thus, problems
surface in the expectation that successful vaccination
of outbred, natural host populations can be predicated
upon studies with inbred, genetically matched
animals. Literature is teeming with laudable results
from parasite vaccination trials performed in rodents
only to be ensued by lackluster data from studies
conducted in large animals. It is unfortunate as well to
consider that many candidate antigens have been cast
aside over the years because of negative results
obtained in rodent models.
The use of host-adapted, laboratory strains of
parasites in research is a well established practice but
not without its problems when in use for vaccine
development. Work by Goyal and Wakelin (1993)
showed significant variation in host responses to
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Trichinella infections in high-responder NIH mice
relative to low-responder C57BL/10 mice. Thus, the
choice of laboratory host can skew our understanding
of protective responses. It has been known that
laboratory strains of rodents can actually select
subpopulations of organisms. Such was the case with
Taenia crassiceps where research showed that after
years of propagation of a fox isolate in laboratory
mice, not only did the parasite lose its ability to
propagate in the natural host, but obvious alterations in
its morphology and antigenic character had also
occurred (Freeman, 1962; Fox et al., 1971). In S.
mansoni, polymorphic loci originally found in a
baboon isolate underwent host-induced selection and
became fixed with time after propagation in mice
(LoVerde et al., 1985). Surprisingly, during these same
studies it was determined that allele-a of phosphoglucose isomerase became fixed in the murine system in
as little as a single generation. With this in mind,
Minchella (1985) proposed that in a parasite–host
assemblage, host imposed selective pressures force
the parasite to make a genetic commitment to coevolution.
7.3. Evolution and vaccines
The process of evolution is among the most
difficult and elusive forces scientists must contend
with in developing parasite vaccines. This problem is
exacerbated with time where co-evolution between the
host and parasite results in the selection of shared
systems of host adaptation and immune evasion, and
thus a microenvironment suitable for the longevity of
the parasite. In some instances, the correlation
between definitive and intermediate hosts may involve
very recent evolutionary events, as is the case with
human taeniids, where the presence of the parasites in
the intermediate hosts (bovine and swine) was likely a
consequence of their recent domestication by man
rather than by vertical transmission from the intermediate host (Hoberg et al., 2001) to hominids. Thus,
in this example, the absence of a well adapted host–
parasite assemblage is one probable impetus for rapid
calcification of the taeniid muscle cysts in their
intermediate hosts, i.e. the host already does a good
job of developing protective immunity. As a result,
one might predict a greater success in achieving near
100% immunity when vaccinating an animal that
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already has a strong natural immunity against
infection (Lightowlers et al., 2003) than in those
situations where the host–parasite relationship has had
sufficient time to evolve. The terminal localisation of
taeniid cysts amidst non-mucosal surfaces, a character
not shared by intestinal parasites of grazing animals,
could also contribute to the extraordinarily high levels
of natural and vaccine-induced protection.
Parasites have developed unique strategies to
obviate immune intervention by the host, such as:
(1) coating themselves in host proteins so as not to be
recognised as foreign; (2) continually producing novel
surface proteins, impairing the effectiveness of the
host’s defense mechanisms; (3) generating components that down-regulate host protective responses; (4)
‘‘mimicking’’, or producing proteins that simulate
host proteins; and in rare cases; (5) intracellular
localisation as is the case with Trichinella. Because of
these and many other avenues of parasite survival,
researchers must contend with the existence of
imperfect (partially effective) rather than sterile
protection, and in so doing the evolution of vaccine
resistance and its relation to virulence. In this regard,
several hypotheses have emerged. One theory suggests
that artificial intervention against parasites can be
classified in two broad categories; those methods that
reduce pathogen growth rate, and those that are
infection-blocking and reduce transmission (Gandon
et al., 2001). In this model, eradication based upon
reducing within-host growth rate will select for higher
virulence whereas those based upon reducing the
probability of infection will select against virulence
and possibly lead to eradication (Gandon et al., 2001,
2003). This theory arises from the trade-off model
(Anderson and May, 1982; Ewald, 1983), which
proposes an association between parasite transmission
and host survival or well-being. Still, there are others
advocating that direct selection against virulence and
not virulence management might be a better approach
(Ebert and Bull, 2003). Both concepts assess the
evolution of virulence generically with respect to the
infectious agent and to this end concede that neither is
a panacea for addressing the problem. In developing
recombinant vaccines against nematodes, however,
transmission potential has often been directly equated
with virulence. Collectively, both modeling and
current data raise the question as to how good do
vaccines have to be to effect the desired results.
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8. How good do worm vaccines have to be?
Before embarking on the arduous task of developing vaccines against any disease agent, it is prudent
to define an achievable endpoint. In the case of
nematodes of ruminants it maybe more appropriate to
consider a vaccine as an epidemiological tool to
maintain low level pasture contamination, rather than
as a weapon to abolish infection completely. Barnes
et al. (1995) developed a mathematical model for
simulating Trichostrongylus populations in grazing
sheep and compared theoretical vaccines of nominal
efficacy with conventional control methods based on
anthelmintic treatment. They concluded that if the
vaccine consisted of a natural antigen, only 60%
efficacy in 80% of the flock would bring substantial
benefits; and if the vaccine was based on a hidden
antigen, then protection of 80% of the flock with 80%
efficacy would give better control than a conventional
anthelmintic programme.
On a similar vein, it has been advocated that a
vaccine which can reduce the O. ostertagi egg output
of first season calves by 60% for the first 2 months
after turn-out, would be sufficient to control bovine
ostertagiosis under North Western European conditions. This conclusion was based on: (1) the bulk of the
pasture contamination in the peak mid summer
months is derived from this early contamination; (2)
because exposed calves rapidly acquire an immunity
which controls Ostertagia fecundity over the peak
period; (3) because effective disease control was
obtained by an anthelmintic preparation of similar
efficacy (Geldhof et al., 2002, 2004).
Approaches to nematode vaccine development
have focused substantially on altering the host’s
immune response to the presence of the organism. In
this way, a successful vaccine historically has been
measured by reducing or eliminating egg output
(transmission potential) or worm burdens (growthrate). Today, however, it may be prudent to consider
alternatives to conventional thinking and appraise the
level of disease rather than the level of parasitism
when determining the efficacy of a vaccine. Such an
approach would include immunizing against pathogenic factors or effects rather than against the
organism itself thereby allowing host-specific antibodies to mitigate the pathology associated with the
infection. This method was evaluated in developing a

vaccine against Trypanosoma congolense in cattle
(Authie et al., 2001). Animals immunised with two
cysteine proteinases and subsequently challenged with
T. congolense showed no substantial effect on the
establishment of infection nor in the development of
acute anaemia; however, immunised cattle maintained
or gained weight during infection and showed
conversion to more normal haematocrit levels after
only 2–3 months of infection. Some would argue that
this might generate unexpected results, such as the
evolution towards higher virulence (Gandon et al.,
2001); however, even in the best models, virulence
evolution can be either positive or negative depending
on the organism’s life-history and host’s heterogeneities. In the end, where model systems seem to target
either transmission or virulence as the best measures
for control, a vaccine directed at both maybe required
for the optimal well-being of the animal.
Alternative mechanisms by, which worm fecundity
and/or survival become attenuated within the host
have been proposed (Viney, 2002). Customary
thinking owes this phenomenon to direct immune
intervention by the host; however, little if any
consideration has been given to indirect attributes,
such as the energy expended by the organism to abate
or counteract the host immune response during
survival. Thus, there is a cost to the worm in terms
of self-protection and repairing damage caused by the
host that must be overcome in order to survive.
Accepting such a premise, Viney (2002) suggests that
new targets for immunisation maybe obtained by
differentially evaluating transcription or protein
patterns from parasites subjected to extreme immune
pressure against those from parasites in naive animals
and under minimal immune pressure. Any observed
changes could be ascribed to the organisms efforts to
mitigate the effects of the stronger immune response
in the challenged animals.

9. Conclusions
Tremendous advances towards worm vaccines for
grazing ruminants have been made in the last decade.
Several highly protective antigens have been discovered, the genes encoding several of these have
been cloned and, in the case of several cestodes at
least, protective recombinant antigens have been
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synthesised. The application of micorarrays, real-time
PCR, RNA interference and proteomics have substantially advanced gene discovery, but as the era of
genome sequencing winds down, scientists must turn
their attentions to linking genomic and proteomic data
to the parasitic nature of an organism in order to target
genes likely involved in host recognition, infection,
and immune evasion. Aside from advances in the art of
gene discovery, however, there remain considerable
hurdles to be overcome before monovalent vaccines
for GI nematodes reach the market place, where the
prospects for multivalent nematode vaccines are more
distant. Specific obstacles include the production of
stable, cost-effective recombinant versions of the
protective antigens with the correct tertiary configuration to elicit effective and prolonged responses, and
identifying appropriate adjuvants for administering
the vaccines. Nonetheless, if the rate of progress in
vaccine development seen in the last 15 years can be
maintained in the years to come, and these advancements can be parallelled by our understanding of
parasitism, it is reasonable to consider that the
introduction of a nematode vaccine will be in reach
before long.
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